FDA Approved Weight Loss Drugs: Why Semaglutide Leads in 2025
The Ascendancy of Semaglutide in FDA-Approved Weight Loss Pharmaceuticals In the rapidly evolving landscape of weight management therapeutics, semaglutide has emerged as a frontrunner among FDA-approved drugs for obesity treatment by 2025. This glucagon-like peptide-1 (GLP-1) receptor agonist has redefined clinical expectations by delivering robust, sustained weight loss outcomes with a favorable safety profile, distinguishing … Read more